🔶 Definium Therapeutics TD Cowen 46th Annual Health Care Conference 🔶

Definium Therapeutics develops innovative psychiatric treatments, with current clinical efforts focused on generalized anxiety disorder and major depressive disorder. Therapeutic candidates include DT120, a proprietary formulation of lysergide (LSD), and DT402, an R-enantiomer formulation of MDMA for autism spectrum disorder. The development pipeline emphasizes scalability and clinical rigor to address unmet patient needs in a growing mental health market. Clinical trials highlight the potential for precise psychedelic medicine, utilizing standardized dosing to achieve robust, durable efficacy without the necessity of intensive psychotherapy intervention. Future milestones involve extensive Phase 3 readouts in 2026, aimed at clearing regulatory pathways.